The reported incidence of prostate cancer, one of the most common cancers in men worldwide, has increased during the last decade as a result of an aging population and more widespread testing of prostate-specific antigen (PSA).[1] Although most of these patients with localized disease can be cured by surgery or radiotherapy, many relapse and eventually develop metastases. The gene discussed is KLK3; the disease is prostate carcinoma.